Pharmaceuticals Global On demand · 24-48h

Global IL-17 Inhibitors for Psoriasis Market Strategic Research Report

Global IL-17 Inhibitors for Psoriasis Market Strategic Resea…
$3,500 USD
Market Research Reports
Strategic Research Report
Global IL-17 Inhibitors for Psoriasis Market
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Bimelizumab, Secukinumab, Ixekizumab, Brodalumab, Vunakizumab, Xeligekimab, Other

By Application: Hospital and Clinic, Pharmacy, Other

Key Players: UCB, Eli Lilly, Novartis, Ortho Dermatologics, LEO Pharma, Kyowa Kirin, Jiangsu Hengrui Pharmaceuticals, Chongqing Genrix Biopharmaceutical

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2024 · forecast to 2032
Length: 104 pages

概観

Scope of the Report

IL-17 inhibitors for psoriasis are a class of biologic drugs designed to target and block the activity of interleukin-17 (IL-17), a pro-inflammatory cytokine that plays a critical role in the pathogenesis of psoriasis. By inhibiting IL-17, these drugs reduce the excessive immune response and help control the symptoms of moderate to severe plaque psoriasis. Examples of IL-17 inhibitors include secukinumab, ixekizumab, brodalumab and so on.

Global key IL-17 Inhibitors for Psoriasis players cover UCB, Eli Lilly, Novartis, Ortho Dermatologics, LEO Pharma, etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global IL-17 Inhibitors for Psoriasis market?

What factors are driving IL-17 Inhibitors for Psoriasis market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do IL-17 Inhibitors for Psoriasis market opportunities vary by end market size?

How does IL-17 Inhibitors for Psoriasis break out by Type, by Application?

This report presents a comprehensive overview of the global IL-17 Inhibitors for Psoriasis market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Bimelizumab
  • Secukinumab
  • Ixekizumab
  • Brodalumab
  • Vunakizumab
  • Xeligekimab
  • Other

Segment by Application

  • Hospital and Clinic
  • Pharmacy
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global IL-17 Inhibitors for Psoriasis market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Hospital and Clinic, Pharmacy, Other evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Segments covered in this report

By Type
BimelizumabSecukinumabIxekizumabBrodalumabVunakizumabXeligekimabOther
By Application
Hospital and ClinicPharmacyOther

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Bimelizumab
  • 3.1.3 Secukinumab
  • 3.1.4 Ixekizumab
  • 3.1.5 Brodalumab
  • 3.1.6 Vunakizumab
  • 3.1.7 Xeligekimab
  • 3.1.8 Other
  • 3.1.9 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Hospital and Clinic
  • 4.1.3 Pharmacy
  • 4.1.4 Other
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 UCB
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Eli Lilly
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Novartis
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Ortho Dermatologics
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 LEO Pharma
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Kyowa Kirin
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Jiangsu Hengrui Pharmaceuticals
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Chongqing Genrix Biopharmaceutical
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How is IL-17 Inhibitors for Psoriasis defined?
IL-17 inhibitors for psoriasis are a class of biologic drugs designed to target and block the activity of interleukin-17 (IL-17), a pro-inflammatory cytokine that plays a critical role in the pathogenesis of psoriasis. By inhibiting IL-17, these drugs reduce the excessive immune response and help control the symptoms of moderate to severe plaque psoriasis. Examples of IL-17 inhibitors include secukinumab, ixekizumab, brodalumab and so on.
How is the IL-17 Inhibitors for Psoriasis market segmented by type?
By type, the market is segmented into Bimelizumab, Secukinumab, Ixekizumab, Brodalumab, Vunakizumab, Xeligekimab and Other.
What are the key applications of IL-17 Inhibitors for Psoriasis?
Key applications covered include Hospital and Clinic, Pharmacy and Other.
Which companies are profiled in the IL-17 Inhibitors for Psoriasis market report?
Key players profiled include UCB, Eli Lilly, Novartis, Ortho Dermatologics, LEO Pharma, Kyowa Kirin, Jiangsu Hengrui Pharmaceuticals and Chongqing Genrix Biopharmaceutical.
What geographies does the IL-17 Inhibitors for Psoriasis market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for IL-17 Inhibitors for Psoriasis?
What factors are driving IL-17 Inhibitors for Psoriasis market growth, globally and by region?
Who should buy the IL-17 Inhibitors for Psoriasis market report?
The report is intended for manufacturers and solution providers, distributors and end users in Hospital and Clinic, Pharmacy and Other, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the IL-17 Inhibitors for Psoriasis market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.